Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM: FARN) (First North: FARON) announced on Monday that its lead candidate, bexmarilimab, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes (MDS).
This designation offers clinical development benefits, including tax credits, user fee exemptions and seven years of marketing exclusivity upon FDA approval.
Bexmarilimab was also granted Orphan Drug Designation for acute myeloid leukemia (AML) by the FDA in August 2023. The drug targets the Clever-1 receptor on macrophages to reprogram myeloid cells, enhancing immune responses and sensitising cancer cells to existing treatments.
Faron is on track to report top-line efficacy results from the frontline and HMA-failed (r/r) MDS patient cohorts of its Phase I/II BEXMAB study in April 2025.
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio
Dermata Therapeutics completes treatment in XYNGARI Phase 3 acne trial
Bloom Science's BL-001 shows positive results in Phase 1 trial
Heyou Hospital, China orders treatment planning system from RaySearch
ONWARD Medical secures funding to advance Parkinson's disease research
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
Raziel and Fosun Pharma commence phase 3 RZL-012 study in China
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
Faron Pharmaceuticals' bexmarilimab receives FDA Orphan Drug Designation for MDS
Protagonist and Takeda report positive Phase 3 results for rusfertide in polycythemia vera
GSK demonstrates significant improvement in CRSwNP treatment with depemokimab at 2025 AAAAI
Australia declines approval for BioArctic and Eisai's Alzheimer's drug lecanemab